S&P 500   4,088.85 (+2.02%)
DOW   32,654.59 (+1.34%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
S&P 500   4,088.85 (+2.02%)
DOW   32,654.59 (+1.34%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
S&P 500   4,088.85 (+2.02%)
DOW   32,654.59 (+1.34%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
S&P 500   4,088.85 (+2.02%)
DOW   32,654.59 (+1.34%)
QQQ   306.17 (+2.59%)
AAPL   149.24 (+2.54%)
MSFT   266.82 (+2.03%)
FB   202.62 (+1.29%)
GOOGL   2,329.46 (+1.77%)
AMZN   2,307.37 (+4.11%)
TSLA   761.61 (+5.14%)
NVDA   181.77 (+5.29%)
BABA   91.99 (+6.37%)
NIO   16.63 (+14.30%)
AMD   102.47 (+8.73%)
CGC   5.89 (+2.79%)
MU   74.48 (+5.69%)
T   20.57 (+1.43%)
GE   76.40 (+2.37%)
F   13.53 (+3.68%)
DIS   108.64 (+3.29%)
AMC   12.90 (+10.16%)
PFE   51.34 (+1.32%)
PYPL   79.75 (+2.70%)
NFLX   190.56 (+2.17%)
NASDAQ:VLON

Vallon Pharmaceuticals (VLON) Stock Forecast, Price & News

$0.59
+0.03 (+5.36%)
(As of 05/17/2022 04:00 PM ET)
Add
Compare
Today's Range
$0.53
$0.61
50-Day Range
$0.56
$7.66
52-Week Range
$0.49
$3.45
Volume
573,481 shs
Average Volume
2.66 million shs
Market Capitalization
$4.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.6
30 days | 90 days | 365 days | Advanced Chart
Receive VLON News and Ratings via Email

Sign-up to receive the latest news and ratings for Vallon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Vallon Pharmaceuticals logo

About Vallon Pharmaceuticals

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel abuse-deterrent medications for central nervous system disorders. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VLON
Fax
N/A
Employees
3
Year Founded
N/A

Sales & Book Value

Annual Sales
$100 thousand
Book Value
$0.85 per share

Profitability

Net Income
$-9.30 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
N/A
Market Cap
$4.02 million
Optionable
Not Optionable

Company Calendar

Today
5/17/2022
Next Earnings (Estimated)
8/09/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.83 out of 5 stars

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -













Vallon Pharmaceuticals (NASDAQ:VLON) Frequently Asked Questions

Is Vallon Pharmaceuticals a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vallon Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Vallon Pharmaceuticals stock.
View analyst ratings for Vallon Pharmaceuticals
or view top-rated stocks.

Are investors shorting Vallon Pharmaceuticals?

Vallon Pharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totaling 320,800 shares, an increase of 134.5% from the April 15th total of 136,800 shares. Based on an average daily volume of 3,430,000 shares, the days-to-cover ratio is currently 0.1 days. Currently, 10.0% of the shares of the stock are sold short.
View Vallon Pharmaceuticals' Short Interest
.

When is Vallon Pharmaceuticals' next earnings date?

Vallon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Vallon Pharmaceuticals
.

What price target have analysts set for VLON?

1 brokers have issued 12 month price targets for Vallon Pharmaceuticals' stock. Their forecasts range from $12.00 to $12.00. On average, they expect Vallon Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 1,933.9% from the stock's current price.
View analysts' price targets for Vallon Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Vallon Pharmaceuticals' key executives?
Vallon Pharmaceuticals' management team includes the following people:
  • Mr. David C. Baker, CEO, Pres & Director (Age 59, Pay $553.55k)
  • Ms. Leanne M. Kelly, CFO & Principal Accounting Officer (Age 45, Pay $328.52k) (LinkedIn Profile)
  • Ms. Penny S. Toren, Sr. VP of Regulatory Affairs & Program Management (Age 55, Pay $294.59k)
  • Dr. Ofir Levi Ph.D., Consulting (Age 48)
  • Dr. Timothy M. Whitaker, Chief Medical Officer (Age 63)
When did Vallon Pharmaceuticals IPO?

(VLON) raised $15 million in an IPO on Wednesday, February 10th 2021. The company issued 1,700,000 shares at $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What is Vallon Pharmaceuticals' stock symbol?

Vallon Pharmaceuticals trades on the NASDAQ under the ticker symbol "VLON."

Who are Vallon Pharmaceuticals' major shareholders?

Vallon Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (1.49%). Company insiders that own Vallon Pharmaceuticals stock include David Charles Baker, Joseph E Payne and Leanne M Kelly.
View institutional ownership trends for Vallon Pharmaceuticals
.

Which major investors are selling Vallon Pharmaceuticals stock?

VLON stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc..
View insider buying and selling activity for Vallon Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Vallon Pharmaceuticals?

Shares of VLON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vallon Pharmaceuticals' stock price today?

One share of VLON stock can currently be purchased for approximately $0.59.

How much money does Vallon Pharmaceuticals make?

Vallon Pharmaceuticals has a market capitalization of $4.02 million and generates $100 thousand in revenue each year. The company earns $-9.30 million in net income (profit) each year or ($1.370010) on an earnings per share basis.

How many employees does Vallon Pharmaceuticals have?

Vallon Pharmaceuticals employs 3 workers across the globe.

What is Vallon Pharmaceuticals' official website?

The official website for Vallon Pharmaceuticals is www.vallon-pharma.com.

How can I contact Vallon Pharmaceuticals?

Vallon Pharmaceuticals' mailing address is TWO LOGAN SQUARE 100 N. 18TH STREET SUITE 300, PHILADELPHIA PA, 19103. The company can be reached via phone at 267-207-3606 or via email at [email protected].

This page was last updated on 5/17/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.